Product Description
Linezolid is used to treat infections, including pneumonia, and infections of the skin . Linezolid is in a class of antibacterials called oxazolidinones. It works by stopping the growth of bacteria. (Sourced from: https://medlineplus.gov/druginfo/meds/a602004.html)
Mechanisms of Action: Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, Georgia, Japan, Moldova, Peru, Philippines, South Africa, South Korea, Spain, Unknown Location, Vietnam
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Fractures, Open|Skin Ulcer|Tuberculosis, Pulmonary|Yaws
Phase 2: Tuberculosis, Multidrug-Resistant
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03828201 |
DRAMATIC | P2 |
Recruiting |
Tuberculosis, Multidrug-Resistant |
2027-05-31 |
50% |
2025-04-30 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
2023-508442-18-00 |
DURATIOM | P3 |
Not yet recruiting |
Fractures, Open |
2027-12-31 |
2025-05-02 |
Treatments |
|
NCT07209761 |
QUANTUM-TB | P3 |
Recruiting |
Tuberculosis, Pulmonary |
2027-05-28 |
24% |
2025-12-11 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT05764876 |
Trep-AByaws | P3 |
Completed |
Skin Ulcer|Yaws |
2024-06-20 |
2025-01-10 |
Primary Endpoints|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/10/2026 |
News Article |
Azurity Pharmaceuticals Announces ARYNTA™ (lisdexamfetamine dimesylate) Oral Solution, CII |
|
02/03/2026 |
News Article |
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results |
|
02/03/2026 |
News Article |
Persica Pharmaceuticals' Positive Clinical Data for PP353 Treatment of Chronic Low Back Pain Published in The Lancet's eClinicalMedicine |
|
02/02/2026 |
News Article |
USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors |